Design Therapeutics Q2 net loss narrower than expected

Design Therapeutics

03/08/2026 13:15

Overview
US biotech firm's Q2 net loss was lower than analyst expectations
Operating expenses for Q2 totaled $22.2 mln
Company ended Q2 with $207.4 mln in cash and securities

Outlook
Company expects to share 12-week RESTORE-FA trial data in Q1 2027
Design to provide update on RESTORE-FA registrational plans in Q4 2026
Company anticipates reporting DM1 and FECD trial data in 2027

Result Drivers
CLINICAL TRIAL PROGRESS - Co cited positive four-week data from RESTORE-FA trial in Friedreich ataxia and modifications to support next-stage development
PIPELINE ADVANCEMENT - Patient dosing began in Phase 1 trial of DT-818 for myotonic dystrophy type 1
PROGRAM DELAYS - FECD trial data now expected in 2027 due to supply delay of DT-168 eye droppers

Company press release: ID:nGNXbMBPbk

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
Beat
$20.17 mln
$21.32 mln (7 Analysts)
Q2 Loss Per Basic Share
 
$0.32
 
Q2 Operating Expenses
 
$22.18 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Design Therapeutics Inc is $21.00, about 72.4% above its July 31 closing price of $12.18

Reuters Recommended Reads
Aug 3 - TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
Aug 3 - Krystal Biotech Q2 revenue rises on VYJUVEK strength
Aug 3 - Ocular Therapeutix Q2 product revenue flat, net loss widens on higher spending

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)